Patent Issued for Determining likely response to combination therapies for cardiovascular disease non-invasively (USPTO 12100149).

Elucid Bioimaging Inc. has been issued a patent for a method of determining likely responses to combination therapies for cardiovascular disease, specifically atherosclerosis. The patent addresses the need for personalized treatment recommendations for patients with cardiovascular disease, which is a leading cause of death globally. The method involves using imaging data of the patient's plaque to generate virtual 'omics data, creating a patient-specific systems biology model. This model is updated with information about the effects of different therapies and is used to simulate the patient's response to combinations of these therapies. The method aims to provide personalized treatment recommendations without invasive tests or biopsies. [Extracted from the article]